Bizon Healthcare announced on the 2nd that it has decided to end the clinical trial following registering a total of 285 patients in the domestic phase 3 clinical trial of the non-narcotic analgesic opirangerine (VVZ-149) injection.
The company judged that it was possible to secure statistical significance because the number of recruited patients exceeded 280.
The phase 3 clinical trial of Opirangerin was conducted at five general hospitals in Korea for patients who had colorectal resection. Seoul National University Hospital, Asan Medical Center, Seoul National University Bundang Hospital, Korea University Anam Hospital, and Samsung Seoul Hospital.
Opirangerin is a non-narcotic treatment that is effective for post-operative pain as a representative pipeline of Vibozon. Similar to opioid analgesics, it can block moderate to severe pain, so it is considered an alternative to the misuse and addiction of existing opioids.
A non-conservative healthcare official said, “Aside from symptoms such as nausea and vomiting, which are common in surgical patients, no serious adverse reactions have been observed so far.” told
Along with the news of the end of this clinical trial, Vivozon mentioned the possibility of joint development of opirangerin with global pharmaceutical companies. Bizon, the developer of opirangerine, introduced its pipeline at the BIO-Europe event held in Leipzig, Germany last month.
“We also received a proposal for joint research on the initial task of a multi-target drug development platform at the last Bio-Europe event,” said Lee Doo-hyeon, chairman of the Vibozon group. “At the JP Morgan Healthcare Conference held early next year, global pharmaceutical companies We asked for the discussion to proceed,” he said.
On the other hand, Bizon Healthcare completed the merger with its subsidiary, Bizon Pharmaceutical, on the 1st. On the 27th of last month, at the extraordinary general meeting of shareholders, it was decided to change the company name to Non-Jeon Pharmaceutical.
